KFS
RUBY

Kelly Financial Services’s Rubius Therapeutics, Inc RUBY Stock Holding History

Kelly Financial Services’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100
Closed -$18 – 735
2022
Q4 		$18 Hold
100
– – ﹤0.01% 685
2022
Q3 		$43 Hold
100
– – ﹤0.01% 684
2022
Q2 		$85 Hold
100
– – ﹤0.01% 663
2022
Q1 		$551 Buy
+100
New +$635 ﹤0.01% 602

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Kelly Financial Services's RUBY Position: Q1 2023 in Review

Kelly Financial Services sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 100 shares — an estimated $18 sold.

Kelly Financial Services first reported a position in RUBY in Q1 2022 and held it in 4 quarters. The position peaked at $551 in Q1 2022. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Kelly Financial Services reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Kelly Financial Services sold 100 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $18.
  • Kelly Financial Services first reported a position in Rubius Therapeutics, Inc in Q1 2022 and held it in 4 quarters.
  • Kelly Financial Services's Rubius Therapeutics, Inc position peaked at $551 in Q1 2022.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Kelly Financial Services's 13F filing for Q1 2023, filed 17 Jul 2024.